{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-097894","form_type":"8-K","ticker":"ABVC","cik":"0001173313","company_name":"ABVC BIOPHARMA, INC.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.839880+00:00","generated_at":"2026-05-30T00:17:21.190991+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"ABVC BioPharma Q3 revenue $389K, net loss narrows to $134K; first operational profit","bullets":["Revenue of $389,276 in Q3 2024 vs $15,884 in Q3 2023, a 2,350% increase.","Net loss narrowed to $134,272 from $3.37M; EPS improved to -$0.02 from -$0.82.","Cash balance grew to $137,344 vs $60,155 at year-end 2023.","Achieved first operational profit but higher interest from convertible debt kept EPS negative.","Licensing agreements could provide up to $292 million; $496K milestone cash received in 9 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-097894","json":"https://secwatch.observer/filing/0001213900-24-097894.json","markdown":"https://secwatch.observer/filing/0001213900-24-097894.md","text":"https://secwatch.observer/filing/0001213900-24-097894.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1173313/000121390024097894/0001213900-24-097894-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1173313/000121390024097894/ea0221143-8k_abvcbio.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:17:21.190991+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}